World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0032426116
Reproduction Date:

Title: Blisibimod  
Author: World Heritage Encyclopedia
Language: English
Subject: Belimumab, B-cell activating factor, Abetimus, Atorolimumab, Aselizumab
Collection: Engineered Proteins
Publisher: World Heritage Encyclopedia


Clinical data
Pregnancy cat.
  • -
Legal status
  • Investigational
CAS number  N
ATC code None
Synonyms A-623
Chemical data
Formula C2836H4376N756O858S26 
Mol. mass 63.6 kDa

Blisibimod (also known as A-623, formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus.[1] It is currently under active investigation in clinical trials.[2]


Blisibimod is a fusion protein consisting of four BAFF binding domains fused to the N-terminus of the fragment crystallizable region (Fc) of a human antibody.[1]

BAFF is involved in B-cell survival, activation, and differentiation.[3] Elevated levels of BAFF have been associated with several B-cell mediated autoimmune diseases, including systemic lupus erythematosus,[4][5][6] lupus nephritis,[7] rheumatoid arthritis,[5][6] multiple sclerosis,[8] Sjögren’s syndrome,[9] Graves’ disease,[10] and Hashimoto's thyroiditis.[10] Blisibimod binds to BAFF and inhibits interaction with BAFF receptors, thus decreasing B-cell survival and proliferation throughout the body.[1][3] Improvements in disease activity have been observed in patients with systemic lupus erythematosus[11] and rheumatoid arthritis[12] following treatment with BAFF inhibitors in clinical trials.


Blisibimod was initially developed by Amgen, with Phase I trials demonstrating comparable safety between the blisibimod and placebo treatments.[1] It was subsequently acquired by Anthera Pharmaceuticals,[13] who in 2010 initiated a global Phase II study called PEARL-SC to investigate the efficacy, safety, and tolerability of blisibimod in subjects with systemic lupus erythematosus.[2][14] The PEARL-SC study, completed in April 2012, yielded data that has been presented at several nephrology-centered conferences, including ACR[15] and EULAR.[16] Blisibimod is currently being tested in a Phase 3 study, CHABLIS-SC1, for Systemic Lupus Erythematosus, and a Phase 2 study, BRIGHT-SC, for IgA nephropathy.


  1. ^ a b c d "A-623: BAFF Peptibody for the Treatment of Lupus". Anthera Pharmaceuticals, Inc. Retrieved 2011-07-08. 
  2. ^ a b "Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS)" (Press release). Anthera Pharmaceuticals, Inc. 29 July 2010. 
  3. ^ a b Browning, J.L. (July 2006). "B cells move to centre stage: novel opportunities for autoimmune disease treatment.". Nature Reviews Drug Discovery 5 (7): 564–76.  
  4. ^ Petri, P.; Stohl, W.; Chatham, W.; McCune, W.J.; Chevrier, M.; Ryel, J.; Recta, V.; Zhong, J.; Freimuth, W. (August 2008). "Association of plasma b lymphocyte stimulator levels and disease activity in systemic lupus erythematosus". Arthritis & Rheumatism 58 (8): 2453–9.  
  5. ^ a b Cheema, G.S.; Roschke, V.; Hilbert, D.M.; Stohl, W. (June 2001). "Elevated serum b lymphocyte stimulator levels in patients with systemic immune–based rheumatic diseases". Arthritis & Rheumatism 44 (6): 1313–9.  
  6. ^ a b Zhang, J.; Roschke, V.; Baker, K.P.; Wang, Z.; Alarcon, G.S.; Fessler, B.J.; Bastian, H.; Kimberly, R.P.; Zhou, T. (January 2001). "Cutting edge: a role for b lymphocyte stimulator in systemic lupus erythematosus". Journal of Immunology 166 (1): 6–10.  
  7. ^ Neusser, M.A.; Lindenmeyer, M.T.; Edenhofer, I.; Gaiser, S.; Kretzler, M.; Regele, H.; Segerer, S.; Cohen, C.D. (January 2011). "Intrarenal production of b-cell survival factors in human lupus nephritis.". Modern Pathology 24 (1): 98–107.  
  8. ^ Krumbholz, M.; Theil, D.; Derfuss, T.; Rosenwald, A.; Schrader, F.; Monoranu, C.M.; Kalled, S.L.; Hess, D.M.; Serafini, B.; Aloisi, F.; Wekerle, H.; Hohlfeld, R.; Meinl, E. (January 2005). "BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma.". Journal of Experimental Medicine 201 (2): 195–200.  
  9. ^ Quartuccio, L.; Fabris, M.; Moretti, M.; Barone, F.; Bombardieri, M.; Rupolo, M.; Lombardi, S.; Pitzalis, C.; Beltrami, C.A.; Curcio, F.; De Vita, S. (2008). "Resistance to rituximab therapy and local BAFF overexpression in sjögren’s syndrome-related myoepithelial sialadenitis and low-grade parotid b-cell lymphoma.". The Open Rheumatology Journal 2: 38–43.  
  10. ^ a b Fabris, M.; Grimaldi, F.; Villalta, D.; Picierno, A.; Fabro, C.; Bolzan, M.; De Vita, S.; Tonutti, E. (January 2010). "BLyS and april serum levels in patients with autoimmune thyroid diseases.". Autoimmunity Reviews 9 (3): 165–9.  
  11. ^ Navarra, S.V.; Guzmán, R.M.; Gallacher, A.E.; Hall, S.; Levy, R.A.; Jimenez, R.E.; Li, E.K.M.; Thomas, M.; Kim, H.; León, M. G.; Tanasescu, C.; Nasonov, E.; Lan, J.L.; Pineda, L.; Zhong, Z.J.; Freimuth, W.; Petri, M.A. (February 2011). "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.". The Lancet 377 (9767): 721–31.  
  12. ^ Genovese, M.C.; Bojin, S.; Biagini, M.; Mociran, E.; Cristei, D.; Georgescu, L.; Sloan-Lancaster, J. (June 2010). "Effects on b cells, safety, and efficacy of LY2127399, a novel anti-BAFF MAB, in patients with active rheumatoid arthritis.". Annals of the Rheumatic Diseases 69 (Suppl3): 69. 
  13. ^ "Anthera Pharmaceuticals acquires the worldwide rights to a BAFF inhibitor for the treatment of lupus and other autoimmune diseases." (Press release). Anthera Pharmaceuticals, Inc. 2008-01-08. 
  14. ^ "PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus.". United States National Institute of Health. Retrieved 2011-07-15. 
  15. ^ "Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting" (Press release). Anthera Pharmaceuticals, Inc. 2012-11-13. 
  16. ^ "Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference" (Press release). Anthera Pharmaceuticals, Inc. 2013-05-07. 
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.